Impact of myocardial scarring on outcomes of cardiac resynchronization therapy: Extent or location?

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 47-54

  Xu, Yi Zhou ^a   Cha, Yong Mei ^a,b,c   Feng, Dali ^d   Powell, Brian D ^a   Wiste, Heather J ^a   Hua, Wei ^c   Chareonthaitawee, Panithaya ^a  

^a MAYO CLINIC   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

^c FUWAI HOSPITAL   (China)

^d Metropolitan Heart and Vascular Institute   (United States)

Author keywords

Cardiac resynchronization therapy; Heart failure; Imaging; Myocardial scarring; Viability

Indexed keywords

AMMONIA N 13; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RADIOISOTOPE; RUBIDIUM 82; SPIRONOLACTONE;

AGED; ANATOMICAL VARIATION; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; MYOCARDIAL PERFUSION IMAGING; MYOCARDIAL SCAR; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; CARDIAC RESYNCHRONIZATION THERAPY; CICATRIX; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL PERFUSION IMAGING; MYOCARDIUM; RETROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84855365336     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.095448     Document Type: Article

References (27)

1. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344-350. (Pubitemid 38944258)
2. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853. (Pubitemid 34603028)
3. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39: 2026-2033. (Pubitemid 34628286)
4. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
5. Cha YM, Rea RF, Wang M, et al. Response to cardiac resynchronization therapy predicts survival in heart failure: a single-center experience. J Cardiovasc Electrophysiol. 2007;18:1015-1019. (Pubitemid 47416574)
6. Bax JJ, Marwick TH, Molhoek SG, et al. Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation. Am J Cardiol. 2003;92:1238-1240. (Pubitemid 37377846)
7. Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy: part 1-issues before device implantation. J Am Coll Cardiol. 2005;46:2153-2167. (Pubitemid 41785481)
8. Aggarwal NR, Martinez MW, Gersh BJ, Chareonthaitawee P. Role of cardiac MRI and nuclear imaging in cardiac resynchronization therapy. Nat Rev Cardiol. 2009;6:759-770.
9. Ypenburg C, Schalij MJ, Bleeker GB, et al. Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients. J Nucl Med. 2006;47:1565-1570. (Pubitemid 47545018)
10. Ypenburg C, Schalij MJ, Bleeker GB, et al. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. Eur Heart J. 2007;28:33-41. (Pubitemid 46134955)
11. Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J. 2007;153:105-112. (Pubitemid 44880886)
12. Sciagra R, Giaccardi M, Porciani MC, et al. Myocardial perfusion imaging using gated SPECT in heart failure patients undergoing cardiac resynchronization therapy. J Nucl Med. 2004;45:164-168.
13. Kennedy JW, Killip T, Fisher LD, Alderman EL, Gillespie MJ, Mock MB. The clinical spectrum of coronary artery disease and its surgical and medical management, 1974-1979. The Coronary Artery Surgery study. Circulation. 1982;66: III16-III23.
14. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-641. (Pubitemid 38229537)
15. Miller TD, Rajagopalan N, Hodge DO, Frye RL, Gibbons RJ. Yield of stress single-photon emission computed tomography in asymptomatic patients with diabetes. Am Heart J. 2004;147:890-896. (Pubitemid 38881004)
16. Rajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ. Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol. 2005;45:43-49. (Pubitemid 40063548)
17. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542. (Pubitemid 34262671)
18. Khandaker MH, Miller TD, Chareonthaitawee P, Askew JW, Hodge DO, Gibbons RJ. Stress single photon emission computed tomography for detection of coronary artery disease and risk stratification of asymptomatic patients at moderate risk. J Nucl Cardiol. 2009;16:516-523.
19. Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med Mol Imaging. 2002;29:1257-1266. (Pubitemid 34985374)
20. Bleeker GB, Bax JJ, Fung JW-H, et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol. 2006;97:260-263. (Pubitemid 43139248)
21. Wokhlu A, Rea RF, Asirvatham SJ, et al. Upgrade and de novo cardiac resynchronization therapy: impact of paced or intrinsic QRS morphology on outcomes and survival. Heart Rhythm. 2009;6:1439-1447.
22. Riedlbauchová L, Brunken R, Jaber WA, et al. The impact of myocardial viability on the clinical outcome of cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2009;20:50-57.
23. Bleeker GB, Kaandorp TA, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation. 2006;113:969-976. (Pubitemid 43879472)
24. Khan FZ, Virdee MS, Begley D, et al. Targeted left ventricular lead placement using speckle tracking echocardiography improves the acute hemodynamic response to cardiac resynchronization therapy: a randomized controlled trial. J Am Coll Cardiol. 2011;57:E2033.
25. Hummel JP, Lindner JR, Belcik JT, et al. Extent of myocardial viability predicts response to biventricular pacing in ischemic cardiomyopathy. Heart Rhythm. 2005;2:1211-1217. (Pubitemid 41614166)
26. Adelstein EC, Tanaka H, Soman P, et al. Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J. 2011;32:93-103.
27. Swindle JP, Rich MW, McCann P, Burroughs TE, Hauptman PJ. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Intern Med. 2010;170:631-637.